Rociletinib (CO1686) was a unique, oral, irreversible TKI designed for NSCLC patients with activity against activating EGFR mutations (L858R and Del 19) and the gatekeeper resistance mutation T790M. Here, EGFR is linked to non-small cell lung carcinoma.